NYSE: WST · Medical Instruments & Supplies
West Pharmaceutical Services (WST) fair value: undervalued or overvalued?
As of 3 Oct 2026, Faircurve's model values West Pharmaceutical Services (WST) at $357.96 a share. The stock last closed at $364.98, which puts the model's fair value 1.9% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 2 Oct 2026. West Pharmaceutical Services, Inc.
Faircurve Insights · 3 Oct 2026
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products.
Faircurve's model found a fair value of $357.96 a share on 3 Oct 2026, the midpoint of 2,000 simulations. The previous run on 26 Sep 2026 gave $363.43, meaning the fair value moved -1.5%. The calibrated range over 63 trading days is $298.65 to $433.96, built from the fair value, and ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium.
The company has an overall quality score of 63 out of 100 against comparable companies. Its quality factors include Profitability 73, Earnings quality 49, Growth quality 71, Capital discipline 29, Balance sheet 93, and Stability 49. The model compares it with ResMed Inc. (RMD), Solventum Corporation (SOLV), Becton, Dickinson and Company (BDX), Baxter International Inc. (BAX), The Cooper Companies, Inc. (COO), Avantor, Inc. (AVTR), Repligen Corporation (RGEN), and AptarGroup, Inc. (ATR). Moves around the last 8 earnings reports ranged from -33.4% to +15.9%, with a median size of 8.0%.
Written from the figures on this page for the 3 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give WST?
The calibrated range for WST over 63 trading days is $298.65 to $433.96. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,809 past valuations, refreshed 3 Oct 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $290.30 to $439.84. In 47% of the simulations the fair value came out above the price the model ran on.
How does WST score on business quality?
West Pharmaceutical Services's overall quality score is 63 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 73 | 19.0%ROIC | 19.1% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 49 | 0.77xFCF / net income | 0.93x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 71 | 6.3%Revenue growth, trailing | 5.4% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 29 | 0.0%Net buybacks / market value | 1.8% |
| Balance sheetNet debt to EBITDA and interest coverage. | 93 | -0.15xNet debt / EBITDA | 1.36x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 49 | 1.9 ptsEBITDA margin downside volatility, 5y | 1.0 pts |
How does WST compare with similar companies?
The companies in medical instruments & supplies closest to West Pharmaceutical Services in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| RMD ResMed Inc. | $218.89 | $223.74 | +2.2% | Fairly valued |
| SOLV Solventum Corporation | $87.85 | $93.45 | +6.4% | Fairly valued |
| BDX Becton, Dickinson and Company | $176.80 | $194.56 | +10.0% | Fairly valued |
| BAX Baxter International Inc. | $23.49 | $23.23 | -1.1% | Fairly valued |
| COO The Cooper Companies, Inc. | $56.91 | $57.15 | +0.4% | Fairly valued |
| AVTR Avantor, Inc. | $15.34 | $17.77 | +15.8% | Undervalued |
| RGEN Repligen Corporation | $181.70 | $144.11 | -20.7% | Overvalued |
| ATR AptarGroup, Inc. | $119.91 | $119.55 | -0.3% | Fairly valued |
All medical instruments & supplies stocks ranked by gap to fair value
When does WST report earnings, and how has the stock reacted?
West Pharmaceutical Services's next earnings report is scheduled for 22 Oct 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 11.5% in either direction through the nearest expiry, about 48 days out, a window that includes the report. That is the size the market is pricing, not a direction.
How WST moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 8.0%.
| Report date | Two session move |
|---|---|
| 23 Jul 2026 | -8.4% |
| 23 Apr 2026 | +11.6% |
| 12 Feb 2026 | +1.8% |
| 23 Oct 2025 | +7.4% |
| 24 Jul 2025 | +15.9% |
| 24 Apr 2025 | -1.7% |
| 13 Feb 2025 | -33.4% |
| 24 Oct 2024 | +7.5% |
West Pharmaceutical Services at a glance
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products.
- Market value
- $25.7B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $3.5B
- Consensus revenue growth, next fiscal year
- +9.8%
- Analysts with estimates
- 10
- Beta to the US market
- 0.57
- First valued by Faircurve
- 1 May 2026
How the fair value is worked out: the model prices West Pharmaceutical Services on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 26 Sep 2026 the model's fair value for WST was $363.43. As of 3 Oct 2026 it is $357.96, a change of -1.5%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about West Pharmaceutical Services's valuation
Is West Pharmaceutical Services stock undervalued or overvalued?
On Faircurve's model, WST reads as Fairly valued as of 3 Oct 2026. The model's fair value is $357.96 a share against a last close of $364.98, a gap of -1.9%.
What is WST's fair value?
$357.96 a share as of 3 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $290.30 to $439.84.
What price range does the model give WST?
$298.65 to $433.96 over 63 trading days. Ranges built this way held the price 60% of the time across 4,809 past valuations, refreshed 3 Oct 2026.
When does West Pharmaceutical Services report earnings next?
The next report is scheduled for 22 Oct 2026. Companies can move their dates.
How much has WST moved on past earnings reports?
Across its last 8 reports the median two session move was 8.0%, ignoring direction. The largest was -33.4% around the report of 13 Feb 2025.
How confident is the model in this valuation?
The model's evidence grade for WST is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.